Cytokinetics vs Enanta Pharmaceuticals
Cytokinetics is the larger business, with $88.0m of revenue in fiscal 2025 against $65.3m for Enanta Pharmaceuticals (1.3 times as much). Cytokinetics grew faster (376.6% against -3.4%). Enanta Pharmaceuticals kept more of each dollar of sales as profit: a net margin of -125.4% against -891.6%.
| Latest fiscal year | CytokineticsCYTK, 2025 | Enanta PharmaceuticalsENTA, 2025 |
|---|---|---|
| Revenue | $88.0m | $65.3m |
| Revenue growth | 376.6% | -3.4% |
| Net income | −$785m | −$81.9m |
| Operating margin | -695.4% | -130.7% |
| Net margin | -891.6% | -125.4% |
| Return on equity | — | -84.6% |
| Free cash flow | −$535m | −$32.2m |
| Cash | $123m | $32.3m |
| Total debt | $999m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 673 | 120 |
| Market value | $7.69bn | $305m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 17 (Weak) |
| Insider trades, 12 months | 0 buys, 85 sales | 0 buys, 9 sales |